The aim of this study was to establish the effect of bacterial endotoxin lipopolysaccharide (LPS) on the release of Type II phospholipase-A 2 (PLA 2 ) and prostaglandin E 2 (PGE 2 ) from late-pregnant human placental tissue incubated in vitro. Under basal conditions, immunoreactive Type II PLA 2 and PGE 2 were released from tissue explants in a time-dependent manner (up to 24 h, ANOVA, P<0·0001, n=6). The release of these mediators was not associated with a loss of cell membrane integrity, as indicated by concentrations of the intracellular enzyme, lactate dehydrogenase (LDH), in the incubation medium. Incubation of explants in the presence of LPS (0·001-100 µg LPS/ml) significantly decreased PLA 2 tissue content (P<0·02, n=6) and increased the accumulation of PLA 2 and PGE 2 in the incubation medium (P<0·0001, n=6) . The data obtained in this study indicated that Type II PLA 2 and PGE 2 are released from term placenta under basal conditions and that LPS stimulated their release. The associated decrease in PLA 2 tissue content is consistent with the hypothesis that LPS induces the release of stored PLA 2 . This study identifies one pathway by which products of bacterial infection may induce the release of a pro-inflammatory, extracellularly active PLA 2 from intrauterine tissues that may promote the formation of phospholipid metabolites involved in the process of labour and delivery (e.g. the prostaglandins).
Introduction
Although the aetiology of preterm labour remains equivocal, reproductive tract bacterial infection has been implicated as a significant risk factor (Daikoku et al. 1982 , Gravett et al. 1986 , Quinn et al. 1987 , Hillier et al. 1988 , Romero et al. 1988 , 1989 . One of the proposed underlying biochemical pathways by which bacterial infection may initiate preterm labour is via bacterial endotoxininduced formation of pro-inflammatory mediators that directly or indirectly promote myometrial responsiveness or activity. Bacterial endotoxins, such as lipopolysaccharide (LPS), induce inflammatory responses in human gestational tissues, resulting in increased release of proinflammatory cytokines, such as cytokine interleukin-1 (IL-1) (Taniguchi et al. 1991 , Kauma et al. 1992 and phospholipid metabolites such as prostanoids (Romero et al. 1988 , Casey et al. 1990 , Mitchell et al. 1990 , Lundin-Schiller & Mitchell 1991 , Nguyen et al. 1994 .
The mechanisms by which LPS affects the formation of phospholipid metabolites in human gestational tissues, and in particular, the primary phospholipase isozyme (Type II phospholipase-A 2 (PLA 2 )) present in human placenta have yet to be established. Type II PLA 2 accounts for greater than 80% of total tissue PLA 2 enzyme activity present in term placenta (Rice et al. 1998) . It is released from gestational tissue and is thought to act on phospholipids in the exoplasmic leaflet of the cell membrane (Farrugia et al. 1997 , Rice et al. 1998 . Type II PLA 2 messenger RNA, immunoreactive content and enzymatic activity have been identified in human gestational tissues, including: amnion, choriodecidua and placenta (Aitken et al. 1990 , Farrugia et al. 1993 , Andersen et al. 1994 . Although the mechanisms that regulate the release of this isozyme from gestational tissues have yet to be determined, increased release of Type II PLA 2 may contribute to the wellcharacterised labour-associated increase in gestational tissue phospholipid metabolism and prostanoid formation (Embrey 1971 , Kierse et al. 1977a ,b, Sellers et al. 1981 and to the increased concentrations of Type II PLA 2 in maternal plasma that occur at this time . In non-gestational tissues, immunohistochemical studies have demonstrated that Type II PLA 2 is located in the secretory granules (Chock et al. 1994) . Thus, increased exocytotic release of Type II PLA 2 may represent one process involved in these labour-associated changes.
The aim of this study was to determine the effects of LPS on placental Type II PLA 2 tissue content and release in vitro and the concomitant release of the prostanoid prostaglandin E 2 (PGE 2 ). The hypothesis to be tested was that LPS-treatment would increase the release of Type II PLA 2 and PGE 2 from placental explants. The experimental model utilised to evaluate the effects of LPS was a well-established placental explant incubation system (Farrugia et al. 1997) .
Material and Methods

Reagents
The following reagents were obtained from BDH Chemicals Australia ( (Turku, Finland) . RPMI 1640(phenol red free), penicillin G and streptomycin were obtained from Gibco Laboratories (Grand Island, NY, USA). Rabbit polyclonal antiserum raised against PGE 2 -porcine thyroglobulin conjugate was provided by Dr P Christensen, Department of Experimental Medicine, The Panum Institute, Copenhagen, Denmark. Type II human PLA 2 monoclonal antibodies (4A1 and 9C1) were prepared by Bioquest (Sydney, NSW, Australia) and recombinant expressed human Type II PLA 2 standard was isolated from Chinese hamster ovary cell line stably transfected with human Type II PLA 2 under a metallothionine promoter (Smith et al. 1992) .
Buffers and extraction medium
The following buffers and extraction media were utilised: PBS (10 mmol/l sodium dihydrogen phosphate, 10 mmol/l di-sodium hydrogen phosphate and 100 mmol/l sodium chloride, pH 7·4), carbonate buffer (20 mmol/l sodium carbonate, 35 mmol/l sodium hydrogen carbonate and 4 mmol/l magnesium chloride, pH 9·8), PLA 2 ELISA washing buffer (135 mmol/l sodium chloride, 3 mmol/l potassium chloride, 2 mmol/l sodium dihydrogen phosphate, 15 mmol/l di-sodium hydrogen phosphate, 0·5 ml/l Tween-20 and 1 g/l BSA, pH 7·4), tissue extraction solution (1 M NaCl), 300 mmol/l sodium chloride, pH 8·0), PGE 2 assay buffer (10 mmol/l dipotassium hydrogen orthophosphate, 10 mmol/l potassium dihydrogen orthophosphate, 0·1% (w/v), 15 mmol/l sodium azide), lactate dehydrogenase (LDH) phosphate buffer (40 mmol/l potassium dihydrogen orthophosphate, 5 mmol/l di-potassium hydrogen orthophosphate, pH 7·0), -NADH (10 mg/ml), LDH solution A (350 µl pyruvic acid (2·5 mg/ml) are added to 9·65 ml LDH phosphate buffer).
Tissue collection and preparation of explants
Human placenta was obtained (with institutional Research and Ethics Committee approval) at elective Caesarean section (i.e. from women before the onset of labour with uncomplicated pregnancies). Seven placentae were used in the experiments on the effects of LPS dose on placental PLA 2 tissue content and a further six placentae were required to investigate the effect of 1 µg/ml LPS on Type II PLA 2 . Tissues were received at the laboratory within 10-15 min of delivery. A section of placenta was placed in ice-cold RPMI 1640. The tissue was teased apart using blunt dissection and placed in RPMI 1640 at 37 C in a humidified atmosphere of carbogen (95% O 2 and 5% CO 2 ) for 1 h. Explants were then blotted dry on sterile filter paper and transferred to 12-well tissue culture plates (Flow Laboratories, McLean, VA, USA) (150-250 mg wet weight/well): the explants were incubated in 2 ml RPMI 1640 or RPMI 1640/LPS containing penicillin G (100 U/ml) and streptomycin (100 µg/ml) for up to 8 h. Media were collected at 1, 2, 4 and 8 h; at each time point 2 ml appropriate incubation medium were completely replaced. The LPS dose experiments were incubated for 24 h with no medium replacement.
Tissue processing
Tissues were homogenised in 1 M NaCl (1:5; w/v) for 20 s using a metal-blade tissue homogeniser (Ultra-turrax, T25 and S25N 8G dispersing tool; Jenke and Kunkel GMBH and Co., Staufen, Germany). The homogenate was centrifuged at 2500 r.p.m. for 10 min at 4 C. The supernate was collected and stored at 20 C until assayed.
Lactate dehydrogenase assay
To negate possible confounding effects of experimental treatments on cell membrane integrity, the release of the intracellular enzyme LDH into incubation medium was determined. A total of 10 µl -NADH were added to 50 µl incubation medium, and 12 µl mixture were transferred to a well in a microtiter plate. A total of 100 µl LDH solution A were then added to each well and immediately mixed in the microplate reader. The microplate reader was programmed to determine absorbance at 340 nm every minute (with 10 s mixing before each reading) for a 10-min duration. Enzyme activity was determined by the rate of change of absorbance, calculated using an extinction coefficient of 6·22 and expressed as a specific activity (µg/mg protein).
Prostaglandin E 2 radioimmunoassay
The concentration of PGE 2 in incubation medium was assayed as described previously (Rice et al. 1988) and fully described by Nguyen et al. (1994) . The sensitivity of the assay averaged 0·02 pmol PGE 2 /tube. The intra-and interassay coefficients of variation were 6·7 and 13·4% respectively. Neither RPMI 1640 nor LPS at concentrations up to 1 µg/ml interfered with the assay.
Type II PLA 2 ELISA
Type II PLA 2 immunoreactivity was quantified by a non-competitive sandwich ELISA using two monoclonal antibodies (9C1 and 4A1) raised against recombinant human Type II PLA 2 as described previously by Farrugia et al. (1993) . The assay was modified by adding an extra wash at each appropriate step. The limit of detection of the assay (defined as two standard deviations from the zero standard) was 0·3 ng/well. The intra-and interassay coefficients of variation determined over ten assays were 8·2 and 8·8% respectively.
Protein assay
The protein content of gestational tissues, homogenates and supernates was determined by the protein dyebinding method described by Bradford (1976) using bovine serum albumin as a reference standard.
Statistical analyses
Statistical computations were performed using a commercially available statistical analysis package (Statgraphics, STSC, Maryland, USA). The homogeneity of data was tested using Bartlett's test (Bartlett 1937) . Where Bartlett's test deviated from homogeneity (P<0·05), the data were transformed and homogeneity of variance confirmed. Significance between individual points was determined using the Newman-Keul's test. Subsequently, two sample comparisons were analysed using Student's t-test, and three or more data sets were analysed using analysis of variance (ANOVA). Statistical significance was indicated by a P value of less than 0·05. Data are expressed as means ...
Results
Phenol red, at a concentration of 0·01 mM (a concentration routinely used in incubation medium) was found to suppress LPS-induced PLA 2 accumulation in incubation medium by 70% compared with incubations free of phenol red. All experiments were therefore carried out in phenol red-free RPMI.
Experiment 1: effect of LPS on placental Type II PLA 2 tissue content
To determine the effect of LPS on Type II PLA 2 tissue content, placental explants were incubated in the absence (control) and presence of increasing concentrations of LPS (0·001-100 µg LPS/ml) for 24 h (Fig. 1) . LPS-treatment was associated with a significant decrease in placental Type II PLA 2 content (P<0·02, n=6). The data were further analysed using post-hoc tests (Student-Newman-Keul's tests) to determine the effects of individual LPS doses. At concentrations of 0·1 µg/ml or greater, LPS significantly reduced Type II PLA 2 tissue content (P<0·05, n=6). No significant effect of LPS on the release of LDH (a marker of cell membrane integrity) was identified. In all subsequent experiments, LPS was used at a concentration of 1·0 µg/ml for 8 h.
Experiment 2: effect of LPS on the release of Type II PLA 2 and PGE 2 from placental explants
To determine the effect of LPS on the concomitant release of Type II PLA 2 and PGE 2 , explants were incubated in the absence (control) or presence of 1·0 µg LPS/ml for up to 8 h. Under basal conditions (i.e. in the absence of LPS), the concentrations of immunoreactive Type II PLA 2 and PGE 2 in incubation medium increased in a timedependant manner over 8 h (ANOVA, P<0·001; n=6) . In the presence of LPS, the release of both Type II PLA 2 and PGE 2 into the incubation medium was significantly increased (P<0·05; n=6). A typical plot is shown in Fig. 2 and group data (n=6) are summarised and presented as (treatment-control) responses in Fig. 3 . No significant effect of incubation time on the accumulation of LDH in incubation medium was identified.
The release of PGE 2 from explants was significantly correlated with Type II PLA 2 release under basal (PGE 2 =5·7 PLA 2 60·5, r 2 =0·90, n=6) and LPSstimulated conditions (PGE 2 =4·1 PLA 2 40·4, r 2 =0·95, n=6).
Discussion
The aim of this study was to determine the effect of bacterial endotoxin (LPS) on the concomitant release of a secreted, extracellularly active PLA 2 isozyme (Type II PLA 2 ) and the prostanoid, PGE 2 , from term placenta. The data obtained are consistent with the hypothesis that Type II PLA 2 is released by term placenta and that the release of isozyme is enhanced by bacterial endotoxin. PGE 2 release from placental explants parallelled, and was significantly correlated with, that of Type II PLA 2 .
Under basal conditions, immunoreactive Type II PLA 2 accumulated in incubation medium in a time-dependent manner (P<0·0001, n=6). The increase in the concentration of phospholipase in incubation medium was not associated with a loss of cell membrane integrity, as indicated by the concentrations of the intracellular enzyme, LDH, in the incubation medium. In the presence of LPS, Type II PLA 2 placental tissue content decreased and incubation medium concentration increased significantly when compared with control incubations (P<0·02, n=6).
Previously, Type II PLA 2 has been localised, using immunohistochemistry and in situ hybridisation, to trophoblast cells, vascular smooth muscle and mesenchymal elements of the placenta (Aitken et al. 1996) . In nongestation tissues, Type II PLA 2 has been identified in secretory granules and is released from tissues via a process of exocytosis (Rosenthal et al. 1995) . In these tissues, the release of Type II PLA 2 has been implicated in the development and progression of inflammatory reactions in response to infection (Vadas & Pruzanski 1986) . By an analogous process, secretory Type II PLA 2 may be induced in human intrauterine tissues in response to infection (e.g. chorioamnionitis) and, in particular, in response to bacterial endotoxin (LPS), resulting in the formation of uterotonic phospholipid metabolites and the premature activation of labour. In support of this proposal, previous studies have identified an association between lower genital tract bacterial infection and human preterm labour (Daikoku et al. 1982 , Gravett et al. 1986 , Quinn et al. 1987 , Hillier et al. 1988 , Romero et al. 1988 , 1989 . In Figure 2 Typical plots of Type II PLA 2 (A) and PGE 2 (B) release from one human placental explant experiment. Explants were incubated in triplicate in the absence () and presence of 1 g/ml LPS () for up to 8 h. Data are expressed as means S.E.M. addition, bacterial endotoxins from gram-negative bacteria have been reported to stimulate the synthesis and release of PGs (e.g. PGE 2 and PGF 2 ) by human gestational tissues (Quinn et al. 1987 , Hillier et al. 1988 , Romero et al. 1989 . Thus, LPS may induce the release of Type II PLA 2 containing secretory granules from placenta tissue. Once released, this phospholipase isozyme may act locally to promote phospholipid hydrolysis and the liberation of substrate for prostanoid synthesis.
In conclusion, this study has characterised the co-release of Type II PLA 2 and PGE 2 from human placenta, under basal and LPS-stimulated conditions. The release of these mediators may contribute to increased intrauterine phospholipid metabolism and the initiation and/or maintenance of labour at term, or preterm in association with reproductive tract bacterial infection. Phenol red, a common additive to tissue culture media, displayed an anti-inflammatory action in suppressing LPS-induced release of Type II PLA 2 .
Figure 3 Release of PLA 2 (A) and PGE 2 (B) from human placental explants. Explants were incubated in absence and presence of 1 g/ml LPS for up to 8 h (n=6). Data were calculated by subtracting control from the LPS-induced value at each time point. LPS produced a significant increase in Type II PLA 2 release from human placental explants; different letters denote significance (ANOVA, P<0·05). Data are expressed as means S.E.M.
